Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BJT-778 in Healthy Volunteers and Subjects with Chronic Hepatitis B and D
2022-502724-46-00Phase 2Terminated
- Sponsor
- Bluejay Therapeutics
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) and Chronic Viral Hepatitis B With Delta-Agent comparing BJT-778 with Placebo (sodium chloride) (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events and clinically significant laboratory abnormalities. Started Jul 2023; status: terminated.
02
Drugs
brelovitug
03
Conditions
Chronic Hepatitis B (CHB)Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on 2022-502724-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502724-46-00.